Recruiting

Nurse-Led Self-Management Program on Taste Alteration in Women With Breast Cancer

Taste alteration is a common and distressing symptom experienced by women with breast cancer receiving taxane-based chemotherapy. This symptom may negatively affect food intake, nutritional status, psychological well-being, and quality of life. Although several approaches have been suggested for the management of chemotherapy-related taste alteration, evidence regarding structured nurse-led self-management interventions in this patient group remains limited.

ClinicalTrials.gov IDNCT07670221

PhaseNA

Enrollment68

SponsorIzmir Bakircay University

Age18 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Chemotherapy-Related Taste Alteration

About this study

Interventions

Behavioral: Nurse-led Self-Management Program — This 8-week nurse-led self-management program is a behavioral supportive care intervention designed specifically for women with breast cancer receiving taxane-based chemotherapy. The program focuses on the self-management of taxane-related taste alteration and associated nutritional problems. It includes structured nurse-led education, regular assessment of taste-related symptoms, self-monitoring of taste changes and food-related difficulties, individualized counseling, goal setting, problem-solving support, and practical strategies to maintain food intake and quality of life during chemotherapy. The intervention is delivered in addition to routine care and differs from general chemotherapy education by specifically integrating taste alteration management, nutritional self-management, and nurse-led follow-up within a structured 8-week program.

Primary outcomes

Change in Chemotherapy-Induced Taste Alteration Scale Score (Baseline, Week 5, and Week 9)
Change in Nutritional Risk Score (Baseline, Week 5, and Week 9)
Change in Quality of Life Score (Baseline, Week 5, and Week 9)

Eligibility information

Inclusion Criteria: * Aged 18 years or older * Literate * Diagnosed with breast cancer * Receiving taxane-based chemotherapy * Having a score of 1 or 2 for taste alteration according to the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) after the first cycle of chemotherapy * Willing to participate in the study and providing written informed consent Exclusion Criteria: * Having any communication barrier that prevents participation in the study * Having a diagnosed psychiatric disorder * Receiving radiotherapy * Having metastasis * Having a diagnosed physical disease that may affect food intake, such as ulcerative colitis or Crohn's disease * Receiving enteral or parenteral nutrition support

Study locations

Izmir Provincal Health Directorate Izmir City Hospital, Izmir, Turkey (Türkiye)

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.